Published in final edited form as:

Genet Epidemiol. 2016 July ; 40(5): 425–431. doi:10.1002/gepi.21971.

Penetrance of *ATM* gene mutations in breast cancer: a meta-analysis of different measures of risk

Monica Marabelli¹, Su-Chun Cheng^{2,3}, Giovanni Parmigiani^{2,3}

¹Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.

²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

³Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Abstract

The gene responsible for ataxia telangiectasia syndrome, *ATM*, is also an intermediate-risk breast cancer susceptibility gene. Numerous studies have been carried out to determine the contribution of *ATM* gene mutations to breast cancer (BC) risk. Epidemiological surveys, segregation analyses and case-control studies reported BC risk in different forms, including penetrance, Relative Risk, Standardized Incidence Ratio and Odds Ratio. Since the reported estimates vary both qualitatively and quantitatively, we developed a general model allowing the integration of the different types of cancer risk available in the literature. We performed a comprehensive meta-analysis identifying 19 studies, and used our model to obtain a consensus estimate of BC penetrance. The cumulative risk of breast cancer in heterozygous *ATM* mutation carriers was estimated to be 6.02% by 50 years of age (95% credible interval: 4.58–7.42%) and 32.83% by 80 years of age (95% credible interval: 24.55–40.43%). An accurate assessment of cancer penetrance is crucial in order to allow mutation carriers to make medical and lifestyle decisions that can reduce their chances of developing the disease.

Keywords

ataxia-telangiectasia mutated (*ATM*) gene; hereditary breast cancer; penetrance; genetic predisposition

Introduction

The ataxia-telangiectasia mutated (*ATM*) gene encodes a protein kinase which plays a central role in the cellular response to DNA double-strand breaks through the phosphorylation of downstream proteins, including BRCA1, p53 and Chk2 [Shiloh and Ziv, 2013]. Homozygous or compound heterozygous mutations in the *ATM* gene are the

Corresponding author: Monica Marabelli, Department of Biology and Biotechnology, University of Pavia, via Ferrata 1, 27100, Pavia, Italy. Telephone: +39 0382 985537, monica.marabelli01@ateneopv.it.

Conflict of interest

The authors declare no conflict of interest.

principal cause of ataxia telangiectasia (AT), an autosomal recessive condition characterized by progressive cerebellar degeneration and oculocutaneous telangiectasia [Chaudhary and Al-Baradie, 2014]. Moreover, heterozygous carriers of *ATM* mutations are at increased risk of breast cancer (BC), although the precise magnitude of such a risk is not yet sufficiently well-established. Studies assessing the BC risk associated with *ATM* mutations fall in three main categories: a) comparison of BC incidence and/or mortality in relatives of AT patients with that in the general population or in spouse controls; b) examination of the pedigrees of mutation carriers to observe co-segregation patterns of *ATM* mutations with the disease; c) case-control studies comparing the frequency of *ATM* mutations in BC patients with that in healthy subjects. Since the designs of these studies are different, they typically provide different measures of BC risks: family-based analyses generally estimate penetrance, Relative Risk (RR) or Standardized Incidence Ratio (SIR), while case-control studies report the Odds Ratio (OR). In addition, the results of these studies are not always concordant, with some detecting a strong association between heterozygous *ATM* mutations and BC susceptibility, while others finding lower evidence of risk. However, the reported findings are not necessarily incompatible, given the large widths of the respective confidence intervals. Overall, epidemiological and molecular analyses estimated that pathogenic mutations in the *ATM* gene confer approximately a 2- to 3-fold increase in breast cancer risk [Turnbull and Rahman, 2008]. It is important to estimate BC risk more precisely, in order to provide appropriate counseling to heterozygous carriers of *ATM* mutations.

The aim of this study is two-fold: to develop a simple and general model allowing the meta-analytic integration of different types of cancer risk estimates, including penetrance, RR, SIR and OR, and to apply this model to estimate the BC penetrance associated with heterozygous *ATM* gene mutations.

Methods

Search strategy and study selection criteria

We performed a PubMed search (up to Feb 10, 2015) of the following keywords in the title/abstract of the articles: ["ATM"] AND ["penetrance" OR "risk"] AND ["breast"]. Additional studies were identified by a manual search of references from original articles and reviews. Inclusion criteria were defined as: 1) family-based segregation analyses or epidemiological studies reporting on cancer risk-related information, including penetrance, RR and SIR; 2) case-control studies comparing BC patients with healthy subjects and reporting either the OR or sufficient data to estimate the OR and its 95% CI. We also included case-control studies in which no mutations were detected in controls (whereby the estimated OR would be infinite), because they still provide useful information for the meta-analysis and excluding them may introduce bias. Papers were excluded for any of the following reasons: studies reporting only on genes or cancers other than *ATM* and BC; articles not published in English; articles reporting on patients already included in larger studies within our set; family-based studies including fewer than 4 families; articles reporting on a spectrum of gene variants but without any usable information on BC risk; studies not conducted in humans; reviews whose relevant citations have already been included in the literature search; meta-analyses whose relevant citations have already been

included in the literature search. Moreover, we excluded papers reporting on *ATM* polymorphisms (MAF>1%) and VUSs (Variants of Uncertain Significance). Many of the studies we selected examined only rare, pathogenic mutations. However, some case-control studies included polymorphisms or VUSs: in these cases, we considered only rare pathogenic or likely pathogenic mutations in our estimate of BC risk.

Statistical analysis

Model description—Let g be the mutation carrier status with $g = 1$ denoting carriers of a deleterious mutation and $g = 0$ non-carriers. We assume that cancer penetrance in mutation carriers is a probability distribution function F_1 , characterized by n parameters $\theta_{11}, \dots, \theta_{1n}$, that is

$$F_1(a; \theta_{11}, \dots, \theta_{1n}) = P(\text{cancer by age } a \mid g = 1)$$

The associated density function is denoted by

$$f_1(a; \theta_{11}, \dots, \theta_{1n})$$

Analogously, we assume that penetrance in non-carriers is a probability distribution function $F_0(a; \theta_{01}, \dots, \theta_{0n})$, with density $f_0(a; \theta_{01}, \dots, \theta_{0n})$.

We assume that studies are independent from each other. Thus the total likelihood $L_T(\theta_{11}, \dots, \theta_{1n})$ for the meta-analysis is the product of all the study-specific contributions $L_s(\theta_{11}, \dots, \theta_{1n})$. We can define each $L_s(\theta_{11}, \dots, \theta_{1n})$ according to the type of study design and cancer risk provided by study s as follows.

Penetrance—Consider a study reporting a single penetrance value $\hat{\mu}$ at age a , with a measure of variability $\hat{\sigma}^2$. Assuming a normal distribution around $\hat{\mu}$, the likelihood function for this study is

$$L_{Pen}(\theta_{11}, \dots, \theta_{1n}) = N(F_1(a; \theta_{11}, \dots, \theta_{1n}), \hat{\mu}, \hat{\sigma}^2)$$

For a study providing m penetrance estimates $\hat{\mu}_1, \dots, \hat{\mu}_m$ or for a study reporting the entire penetrance curve after we discretize the function in m values $\hat{\mu}_1, \dots, \hat{\mu}_m$, we assume that the likelihood function is a multivariate normal distribution

$$L_{Pen}(\theta_{11}, \dots, \theta_{1n}) = N \left(\begin{pmatrix} F_1(a_1; \theta_{11}, \dots, \theta_{1n}) \\ \vdots \\ F_1(a_m; \theta_{11}, \dots, \theta_{1n}) \end{pmatrix}, \begin{pmatrix} \hat{\mu}_1 \\ \vdots \\ \hat{\mu}_m \end{pmatrix}, \begin{pmatrix} \hat{\sigma}_{11} & \dots & \hat{\sigma}_{1m} \\ \vdots & \ddots & \vdots \\ \hat{\sigma}_{1m} & \dots & \hat{\sigma}_{mm} \end{pmatrix} \right)$$

The off-diagonal elements of the covariance matrix account for dependencies among penetrance estimates at different ages.

Relative Risk (RR)—The RR is generally defined as

$$RR = \frac{P(\text{cancer} \mid g = 1)}{P(\text{cancer} \mid g = 0)}$$

where “cancer” refers to the event that an individual is observed with cancer within a study. In studies reporting estimates of RR without individual-level data, our challenge is to express the study-specific likelihood in terms of the penetrance function parameters. A simple approximation is feasible if one can estimate, or make reasonable assumptions about, the distributions $G(a \mid g)$ $g = 0, 1$ of ages of carriers and non-carriers in the study. On average:

$$P(\text{cancer} \mid g) = \int P(\text{cancer by age } a \mid g) G(a \mid g) da$$

Assuming specifically that $G(a \mid g = 1) = N(a, A_1, V_1^2)$ and $G(a \mid g = 0) = N(a, A_0, V_0^2)$, we propose approximating the likelihood function as

$$L_{RR}(\theta_{11}, \dots, \theta_{1n}) = N\left(\frac{\int F_1(a; \theta_{11}, \dots, \theta_{1n}) N(a, A_1, V_1^2) da}{\int F_0(a; \theta_{01}, \dots, \theta_{0n}) N(a, A_0, V_0^2) da}, \hat{\mu}, \hat{\sigma}^2\right)$$

where $\hat{\mu}$ and $\hat{\sigma}^2$ are the reported RR and the corresponding measure of variability.

In practice, even $G(a \mid g)$ may not always be available, in which case it is still possible to make progress using the distribution $Q(a \mid g)$ $g = 0, 1$ of ages of onset among carriers and non-carriers, and approximating the cancer rates by the average:

$$P(\text{cancer at any age} \mid g) = \int P(\text{cancer at age } a \mid g) Q(a \mid g) da$$

where P is the penetrance common to all studies in the analysis, while Q is the study-specific distribution of ages at cancer onset. Under normality assumption for Q , the likelihood can be approximated by

$$L_{RR}(\theta_{11}, \dots, \theta_{1n}) = N\left(\frac{\int f_1(a; \theta_{11}, \dots, \theta_{1n}) N(a, A_1, V_1^2) da}{\int f_0(a; \theta_{01}, \dots, \theta_{0n}) N(a, A_0, V_0^2) da}, \hat{\mu}, \hat{\sigma}^2\right)$$

This approach is less desirable than the one above it because it does not consider ages of unaffected study participants.

Standardized Incidence Ratio (SIR)—The SIR is obtained by dividing the observed number of cancer cases among mutation carriers by the number of cases expected on the basis of the disease rate in the general population. Therefore, similarly to the RR, one can approximate via distributions G or Q . In the latter case the likelihood can be approximated as

$$L_{SIR}(\theta_{11}, \dots, \theta_{1n}) = N \left(\frac{\int f_1(a; \theta_{11}, \dots, \theta_{1n}) N(a, A_1, V_1^2) da}{P(g=1) \int f_1(a; \theta_{11}, \dots, \theta_{1n}) N(a, A_1, V_1^2) da + P(g=0) \int f_0(a; \theta_{01}, \dots, \theta_{0n}) N(a, A_0, V_0^2) da}, \hat{\mu}, \hat{\sigma}^2 \right)$$

where $P(g=1)$ and $P(g=0)$ are the population frequencies of carriers and non-carriers, respectively.

Odds Ratio (OR)—Here we consider a case-control design. We let

$$P_{g|c} = P(g=1 \mid \text{cancer at any age})$$

$$P_{g|h} = P(g=1 \mid \text{health at age of inclusion in study})$$

The Odds Ratio can be defined as

$$OR = \frac{\frac{P_{g|c}}{1 - P_{g|c}}}{\frac{P_{g|h}}{1 - P_{g|h}}}$$

Using Bayes' theorem, we obtain

$$P_{g|c} = \frac{P(g=1)P(\text{cancer at any age} \mid g=1)}{\sum_{j=0}^1 P(g=j)P(\text{cancer at any age} \mid g=j)}$$

and

$$1 - P_{g|c} = \frac{P(g=0)P(\text{cancer at any age} \mid g=0)}{\sum_{j=0}^1 P(g=j)P(\text{cancer at any age} \mid g=j)}$$

Therefore, using approximations similar to those described for the RR case

$$\begin{aligned} \frac{P_{g|c}}{1 - P_{g|c}} &= \frac{P(g=1)P(\text{cancer at any age} \mid g=1)}{P(g=0)P(\text{cancer at any age} \mid g=0)} \\ &= \frac{P(g=1) \int f_1(a; \theta_{11}, \dots, \theta_{1n}) N_c(a, A_1, V_1^2) da}{P(g=0) \int f_0(a; \theta_{01}, \dots, \theta_{0n}) N_c(a, A_0, V_0^2) da} \end{aligned}$$

assuming that in breast cancer patients the age of onset distributions in the study are $Q_c(a \mid g=1) = N_c(a, A_1, V_1^2)$ and $Q_c(a \mid g=0) = N_c(a, A_0, V_0^2)$. Similarly, assuming that in healthy controls the ages at inclusion in the study are $G_h(a \mid g=1) = N_h(a, A_1, V_1^2)$ and $G_h(a \mid g=0) = N_h(a, A_0, V_0^2)$, then

$$\begin{aligned} \frac{P_g | h}{1 - P_g | h} &= \frac{P(g=1)P(\text{health at age of inclusion in study} | g=1)}{P(g=0)P(\text{health at age of inclusion in study} | g=0)} \\ &= \frac{P(g=1) \int (1 - F_1(a; \theta_{11}, \dots, \theta_{1n})) N_h(a, A_1, V_1^2) da}{P(g=0) \int (1 - F_0(a; \theta_{01}, \dots, \theta_{0n})) N_h(a, A_0, V_0^2) da} \end{aligned}$$

where $1 - F_1(a; \theta_{11}, \dots, \theta_{1n})$ and $1 - F_0(a; \theta_{01}, \dots, \theta_{0n})$ are the disease-free survival functions by age a in carriers and non-carriers, respectively.

As a consequence,

$$L_{OR}(\theta_{11}, \dots, \theta_{1n}) = N \left(\frac{\frac{\int f_1(a; \theta_{11}, \dots, \theta_{1n}) N_c(a, A_1, V_1^2) da}{\int f_0(a; \theta_{01}, \dots, \theta_{0n}) N_c(a, A_1, V_0^2) da}}{\frac{\int (1 - F_1(a; \theta_{11}, \dots, \theta_{1n})) N_h(a, A_1, V_1^2) da}{\int (1 - F_0(a; \theta_{01}, \dots, \theta_{0n})) N_h(a, A_1, V_0^2) da}}, \hat{\mu}, \hat{\sigma}^2 \right)$$

Case-control studies generally report not only the OR itself, but also the numerators and the denominators separately. In that case it may be preferable to write the likelihood as the product of two binomial distributions considering these terms separately, rather than the likelihood of the OR, which implies loss of useful information.

Let m_c and m_h be the number of mutated cases and the number of mutated healthy controls, respectively, while n_c and n_h the number of non-mutated cases and controls, respectively. The likelihood function can be written as

$$\begin{aligned} L_{Bin}(\theta_{11}, \dots, \theta_{1n}) &= B \left(m_c, m_c + n_c, \frac{P(g=1) \int f_1(a; \theta_{11}, \dots, \theta_{1n}) N_c(a, A_1, V_1^2) da}{\sum_{j=0}^1 P(g=j) \int f_j(a; \theta_{j1}, \dots, \theta_{jn}) N_c(a, A_j, V_j^2) da} \right) \\ &\times B \left(m_h, m_h + n_h, \frac{P(g=1) \int (1 - F_1(a; \theta_{11}, \dots, \theta_{1n})) N_h(a, A_1, V_1^2) da}{\sum_{j=0}^1 P(g=j) \int (1 - F_j(a; \theta_{j1}, \dots, \theta_{jn})) N_h(a, A_j, V_j^2) da} \right) \end{aligned}$$

Model specification for ATM analysis—In our meta-analysis, we assumed that BC penetrance associated with *ATM* heterozygous mutations is a Weibull distribution F_1 , characterized by parameters κ and λ . The cumulative penetrance function is

$$F_1(a; \kappa, \lambda) = 1 - e^{-\left(\frac{a}{\lambda}\right)^\kappa} \text{ and the corresponding density is } f_1(a; \kappa, \lambda) = \frac{\kappa}{\lambda^\kappa} a^{\kappa-1} e^{-\left(\frac{a}{\lambda}\right)^\kappa}. \text{ We}$$

chose this distribution because, among commonly used parametric curves, it is the most similar to cancer penetrance curves reported in the literature (*e.g.* Goldgar *et al.*, 2011). It is very rare to develop BC before 15 years of age; therefore to improve fit we performed the analysis using a “breast age” $a = \text{age} - 15$.

We assumed that non-carriers and healthy controls have approximately the same penetrance of the general population, as *ATM* mutations are sufficiently rare. We assumed that this penetrance is also Weibull, with parameters κ_0 and λ_0 estimated from Surveillance, Epidemiology, and End Results data for the US population (SEER 18 Registries, Incidence, 2008–2012; <http://seer.cancer.gov/faststats/selections.php?series=cancer>).

Wherever possible, we used distributions Q reported in the corresponding papers. If Q is not specified in the paper, we used the mean age at BC diagnosis and variance of the US general population. Moreover, case-control studies generally provide only the mean age at diagnosis of BC patients and the mean age of healthy controls; therefore, we assumed that $Q_C(a | g = 1) = Q_C(a | g = 0)$ and $G_H(a | g = 1) = G_H(a | g = 0)$. If the mean age and variance of healthy subjects was not explicitly indicated, we assumed that $Q_C(a | g = j) = G_H(a | g = j)$.

Of relevance, $P(g = 1)$ for the *ATM* pathogenic mutations is not yet well-established. Therefore, for papers providing the SIR, we used L_{RR} instead of L_{SIR} , assuming that BC incidence in the general population is the same as in non-carriers. Similarly, the methodology with L_{Bin} is potentially more efficient, because it incorporates additional information separately at the numerator and at the denominator of the Odds Ratio; however, it has the disadvantage of requiring a good external estimate of the prevalence $P(g = 1)$. Therefore, in this particular application we decided to use L_{OR} . To estimate the Odds Ratio for case-control studies in which no mutations were detected in controls (OR theoretically infinite), we added .5 to each cell of the (2×2) table, as suggested by Haldane [1955] and Gart and Zweifel [1967]. In the RR studies, information on G was not available, and thus we approximated the likelihood using Q .

We estimated κ and λ using the maximum likelihood approach. To assess uncertainty, we used a Bayesian approach: assuming that the prior distribution of κ and λ is uniform, we obtained the 95% credible intervals based on posterior probability distributions. More specifically, we drew random pairs of κ and λ uniformly within a suitably broad range (for κ we used 1 through 6 and for λ we used 40 through 500); we calculated the likelihood values for each pair drawn; we used as weights the renormalized likelihood values; we calculated the penetrance values for each pair at different ages (40, 50, 60, 70, 80 years); we sorted the penetrance values keeping the corresponding weights; we cut the cumulative sum of the weights at 0.025 and 0.975 to provide 95% credible intervals. A potential limitation of this method is that intervals do not incorporate study-to-study variation, as the studies are assumed to be independent.

Statistical analysis was performed using the R (version 3.2.0) software [Ihaka and Gentleman, 1996]. R code for analysis is available upon request.

Results

Meta-analysis results

In total, 19 papers were selected by our search criteria. Table 1 shows the main characteristics of the studies selected in the meta-analysis.

The studies are heterogeneous in terms of population, patient ascertainment, study design and type of BC risk reported. In the Methods section we described a model that allowed us to integrate these different kinds of BC risks and to estimate the penetrance of heterozygous *ATM* gene mutations, taking into account the contribution of each paper. Results are shown in Figure 1A. The parameters of the Weibull distribution are estimated to be: $\kappa = 3.00$; $\lambda = 88.37$. The corresponding penetrance is estimated to be 6.02% by 50 years of age (95%

credible interval: 4.58–7.42%) and 32.83% by 80 years of age (95% credible interval: 24.55–40.43%).

Sensitivity analysis

To explore if any of the individual studies disproportionately affected our estimates, we performed a leave-one-study-out analysis, in which each of the 19 studies was removed in turn. We inspected the 19 resulting curves, and then estimated the average curve, taking into account the sample size of the excluded paper in order to give a lower weight to those curves obtained after the removal of a large paper. The average curve is no longer constrained to the Weibull form: it is a mixture of Weibull distributions. The 19 resulting penetrance curves, as well as the weighted average curve, are shown in Figure 1B.

Our estimates generally show little sensitivity to the removal of individual studies, indicating that our results are likely to be robust. Moreover, the average curve resulting from the tests of sensitivity is nearly identical to the curve obtained including all the 19 studies. Specifically, the cumulative risk of breast cancer by age 50 is estimated to be 6.02% according to the all-inclusive curve and 5.98% according to the weighted average curve, while the cumulative risk by age 80 is estimated to be 32.83% and 32.65% according to the all-inclusive curve and the weighted average curve, respectively.

Discussion

Three categories of BC susceptibility alleles are currently described. High-penetrance genes, such as *BRCA1* and *BRCA2*, are characterized by multiple, individually rare, loss-of-function mutations that confer a high BC risk ($RR > 10$). Low-penetrance variants, identified through genome-wide association studies, are common but associated with small increases in risk (RR 1.08–1.26). Finally, moderate-penetrance genes, including *ATM*, *CHEK2*, *BRIP1* and *PALB2*, are characterized by rare, loss-of-function mutations that confer intermediate risks (RR 2–4) [Turnbull and Rahman, 2008].

After the first observation that female relatives of AT patients are at increased risk of developing breast cancer [Swift, 1976], numerous studies have been performed to clarify the role of *ATM* gene in BC susceptibility and to quantify such a risk. As a result of the diverse designs of published studies, different types of BC risk are available in the literature: some papers reported a full estimate of the penetrance curve, others estimated the BC risk of *ATM* mutation carriers relative to non-carriers (RR) or to the general population (SIR), while case-control studies evaluated the proportion of carriers among patients and healthy subjects and reported the OR . The goal of this study was to perform a meta-analysis including all the information available in the literature, and to integrate the different measures of BC risk into a single penetrance analysis. Of note, *ATM* truncating-mutations might have a different effect on *ATM* activity and hence on cancer susceptibility compared with missense variants [Gatti *et al.*, 1999]. Evidence exists that the most severe missense substitutions, falling in specific *ATM* domains, actually confer greater risk of breast cancer than protein-truncating mutations [Tavtigian *et al.*, 2009; Tavtigian and Chenevix-Trench, 2014]. If this were the case, it would be interesting to estimate the different penetrance associated with distinct types of mutation. However, the majority of the papers identified in our search included

mixed pool of mutation types; therefore it was not feasible to separate the effects of these types of mutations in our analysis. Instead, it seemed more reasonable to consider the average risk among a group of carriers with a representative mix of pathogenic mutations.

The model developed here allowed us to estimate the penetrance of breast cancer in carriers of a pathogenic *ATM* allele. We also performed a sensitivity analysis by omitting each study in turn, to identify potential outlying studies, which may have impact on between-study heterogeneity. Assessing heterogeneity across studies in a meta-analysis is a crucial issue. We found it challenging to use traditional methods, because we use a two-parameter model for the penetrance, but some studies only report a single summary statistic. While these studies are informative when incorporated in the overall analysis, if taken in isolation do not provide meaningful penetrance estimates. Accordingly, we decided to address the issue of heterogeneity in a way that is free from the choice of study-specific summary statistics, and accomplished this through the use of a leave-one-study-out analysis. Penetrance estimates were generally insensitive to the removal of individual studies. The most influential when removed is Thompson *et al.* [2005] (dotted line in Figure 1B), which was performed on a very large group of AT relatives, and is one of two papers, together with Goldgar *et al.* [2011], to provide the entire penetrance curve with 95% CI. Therefore, it gives an important contribution to the meta-analysis and its exclusion has a comparatively higher effect on our estimates of BC risk. Even in that case, after the removal of Thompson *et al.* the penetrance is not substantially altered and the curve estimated by the meta-analysis, which includes all the 19 papers, is very similar to the average curve obtained after the sensitivity tests, indicating that our findings are likely to be robust.

To the best of our knowledge, our meta-analysis of different types of cancer risk is unique in the biomedical literature. The advantage of our strategy is the possibility of using all the information available in the literature, which should lead to a more precise estimate of penetrance. A potential limitation is the reliance on a parametric form for the penetrance, dictated by the paucity of studies reporting sufficient detail to use more flexible models. Parametric assumption can be hard to check and to relax when most studies report RR or OR. Nonetheless, the general approach described in the Methods could be implemented in a more flexible way if data are richer. The model we built here could also be used to estimate the risk associated with mutations in other genes suspected to play a role in cancer susceptibility and other types of cancer, with no restriction on the type of mutation (heterozygous or homozygous; rare or common). It is important to get an accurate quantification of cancer risk, in order to include mutation carriers in appropriate cancer surveillance programs and help them to evaluate the possibility of undergoing surgical interventions that can reduce their chances of developing the disease.

Acknowledgements

Monica Marabelli received support from the Pavia-Boston project, promoted by the University of Pavia. Giovanni Parmigiani and Su-Chun Cheng received support from NCI grant 5R21CA177233-02.

References

- Allinen M, Launonen V, Laake K, Jansen L, Huusko P, Kääriäinen H, Børresen-Dale AL, Winqvist R. 2002 *ATM* mutations in Finnish breast cancer patients. *J Med Genet* 39:192–6. [PubMed: 11897822]
- Andrieu N, Cavaciuti E, Laugé A, Ossian K, Janin N, Hall J, Stoppa-Lyonnet D. 2005 Ataxia-telangiectasia genes and breast cancer risk in a French family study. *J Dairy Res* 72 Spec No:73–80. [PubMed: 16180724]
- Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, Antonenkova NN, Khusnutdinova E, Lubinski J, Dörk T. 2009 A nonsense mutation (E1978X) in the *ATM* gene is associated with breast cancer. *Breast Cancer Res Treat* 118:207–11. [PubMed: 18807267]
- Brunet J, Gutiérrez-Enríquez S, Torres A, Bérez V, Sanjosé S, Galceran J, Izquierdo A, Menéndez JA, Gumà J, Borràs J. 2008 *ATM* germline mutations in Spanish early-onset breast cancer patients negative for *BRCA1/BRCA2* mutations. *Clin Genet* 73:465–73. [PubMed: 18384426]
- Chaudhary MW, Al-Baradie RS. 2014 Ataxia-telangiectasia: future prospects. *Appl Clin Genet* 7:159–67. [PubMed: 25258552]
- FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. 1997 Heterozygous *ATM* mutations do not contribute to early onset of breast cancer. *Nat Genet* 15:307–10. [PubMed: 9054948]
- Gart JJ, Zweifel JR. 1967 On the bias of various estimators of the logit and its variance with application to quantal bioassay. *Biometrika* 54:181–7. [PubMed: 6049534]
- Gatti RA, Tward A, Concannon P. 1999 Cancer risk in *ATM* heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. *Mol Genet Metab* 68:419–23. [PubMed: 10607471]
- Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM; BCFR; kConFab, Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. 2011 Rare variants in the *ATM* gene and risk of breast cancer. *Breast Cancer Res* 13:R73. [PubMed: 21787400]
- Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J. 2011 Germline *ATM* mutational analysis in *BRCA1/BRCA2* negative hereditary breast cancer families by MALDI-TOF mass spectrometry. *Breast Cancer Res Treat* 128:573–9. [PubMed: 21445571]
- Haldane JBS. 1955 The estimation and significance of the logarithm of a ratio of frequencies. *Ann Hum Genet* 20:309–11.
- Ihaka R, Gentleman R. 1996 R: A language for data analysis and graphics. *Journal of Computational and Graphical Statistics* 5:299–314.
- Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, Jacobs C, Liebmann R, Zvelebil MJ, Mathew C, Solomon E. 1999 Identification of germline missense mutations and rare allelic variants in the *ATM* gene in early-onset breast cancer. *Genes Chromosomes Cancer* 26:286–94. [PubMed: 10534763]
- Kreiss Y, Barak F, Baruch RG, Levy-Lahad E, Pras E, Friedman E. 2000 The founder mutations in the *BRCA1*, *BRCA2*, and *ATM* genes in Moroccan Jewish women with breast cancer. *Genet Test* 4:403–7. [PubMed: 11216667]
- Mangone FR, Miracca EC, Feilotter HE, Mulligan LM, Nagai MA. 2015 *ATM* gene mutations in sporadic breast cancer patients from Brazil. *Springerplus* 4:23. [PubMed: 25625042]
- Olsen JH, Hahnemann JM, Børresen-Dale AL, Tretli S, Kleinerman R, Sankila R, Hammarström L, Røbsahm TE, Kääriäinen H, Bregård A, Brøndum-Nielsen K, Yuen J, Tucker M. 2005 Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. *Br J Cancer* 93:260–5. [PubMed: 15942625]
- Pylkäs K, Tommiska J, Syrjäkoski K, Kere J, Gatei M, Waddell N, Allinen M, Karppinen SM, Rapakko K, Kääriäinen H, Aittomäki K, Blomqvist C, Mustonen A, Holli K, Khanna KK, Kallioniemi OP, Nevanlinna H, Winqvist R. 2007 Evaluation of the role of Finnish ataxia-

telangiectasia mutations in hereditary predisposition to breast cancer. *Carcinogenesis* 28:1040–5. [PubMed: 17166884]

- Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N. 2006 *ATM* mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet* 38:873–5. [PubMed: 16832357]
- Shiloh Y, Ziv Y. 2013 The *ATM* protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat Rev Mol Cell Biol* 14:197–210.
- Soukupova J, Dundr P, Kleibl Z, Pohlreich P. 2008 Contribution of mutations in *ATM* to breast cancer development in the Czech population. *Oncol Rep* 19:1505–10. [PubMed: 18497957]
- Swift M. 1976 Malignant neoplasms in the families of patients with ataxia-telangiectasia. *Cancer Res* 36:209–15. [PubMed: 1248000]
- Swift M, Lukin JL. 2008 Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene. *Cancer Epidemiol Biomarkers Prev* 17:3188–92. [PubMed: 18990761]
- Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegelé C, Webb PM, Whiteman DC; Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuninghame Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Sangrajang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. 2009 Rare, evolutionarily unlikely missense substitutions in *ATM* confer increased risk of breast cancer. *Am J Hum Genet* 85:427–46. [PubMed: 19781682]
- Tavtigian SV, Chenevix-Trench G. 2014 Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. *Biomark Med* 8:589–603. [PubMed: 24796624]
- Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P. 2001 Increased frequency of *ATM* mutations in breast carcinoma patients with early onset disease and positive family history. *Cancer* 92:479–87. [PubMed: 11505391]
- Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. 2005 Cancer risks and mortality in heterozygous *ATM* mutation carriers. *J Natl Cancer Inst* 97:813–22. [PubMed: 15928302]
- Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM, Oefner PJ. 2003 Contributions of *ATM* mutations to familial breast and ovarian cancer. *Cancer Res* 63:3325–33. [PubMed: 12810666]
- Turnbull C, Rahman N. 2008 Genetic predisposition to breast cancer: past, present, and future. *Annu Rev Genomics Hum Genet* 9:321–45. [PubMed: 18544032]
- Turnbull C, Seal S, Renwick A, Warren-Perry M, Hughes D, Elliott A, Pernet D, Peock S, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L; Breast Cancer Susceptibility Collaboration (UK), EMBRACE, Ahmed M, Eccles D, Evans DG, Donnelly P, Easton DF, Stratton MR, Rahman N. 2012 Gene-gene interactions in breast cancer susceptibility. *Hum Mol Genet* 21:958–62. [PubMed: 22072393]

Figure 1.

(A) Solid line: cumulative risk of breast cancer in heterozygous *ATM* mutation carriers along with 95% credible intervals (Weibull parameters: $\kappa = 3.00$; $\lambda = 88.37$). Dashed line: cumulative risk of breast cancer in non-carriers (Weibull parameters derived from SEER data for the US population: $\kappa_0 = 2.25$; $\lambda_0 = 159.71$). (B) Dashed/dotted lines: penetrance curves obtained in the leave-one-study-out tests of sensitivity (the curve obtained after removal of Thompson *et al.*, 2005 is indicated with the dotted line). Solid line: weighted average of dashed/dotted lines.

Table 1.

Characteristics of the studies included in the meta-analysis

Study	Country	Case eligibility criteria	Study design	BC risk
Goldgar <i>et al.</i> , 2011	USA, Canada, Australia, New Zealand	familial BC, <i>BRCA1/2</i> negative	family-based segregation analysis	Penetrance curve
Thompson <i>et al.</i> , 2005	UK	one family member with AT	cancer incidence in relatives of AT patients	Penetrance curve
Swift and Lukin, 2008	USA, Canada	one family member with AT	cancer incidence in relatives of AT patients	RR
Renwick <i>et al.</i> , 2006	UK	familial BC, <i>BRCA1/2</i> negative	case-control/family-based segregation analysis	RR
Olsen <i>et al.</i> , 2005	Denmark, Finland, Norway, Sweden	one family member with AT	cancer incidence in relatives of AT patients	SIR
Andrieu <i>et al.</i> , 2005	France	one family member with AT	cancer incidence in relatives of AT patients	SIR
Bogdanova <i>et al.</i> , 2009	Belarus, Russia, Poland	mainly unselected BC, except for a small group of familial BC and a group of early-onset BC (<50y)	case-control study	OR
Pylkäs <i>et al.</i> , 2007	Finland	familial and unselected BC, <i>BRCA1/2</i> negative	case-control study	OR
Kreiss <i>et al.</i> , 2000	Morocco (Jewish)	unselected BC	case-control study	OR ^a
Turnbull <i>et al.</i> , 2012	UK	familial BC	case-control study	OR ^a
FitzGerald <i>et al.</i> , 1997	USA	early-onset BC (<40y)	case-control study	OR ^a
Teraoka <i>et al.</i> , 2001	USA	early-onset BC (<35y) and/or family history of BC	case-control study	NA ^b
Graña <i>et al.</i> , 2011	Spain	high-risk familial BC, <i>BRCA1/2</i> negative	case-control study	NA
Soukupova <i>et al.</i> , 2008	Czech Republic	familial or early-onset BC (<40y; if bilateral <50y), <i>BRCA1/2</i> negative	case-control study	NA ^b
Brunet <i>et al.</i> , 2008	Spain	unselected early-onset BC (<46y), <i>BRCA1/2</i> negative	case-control study	NA ^b
Mangone <i>et al.</i> , 2015	Brazil	sporadic BC	case-control study	NA ^b
Allinen <i>et al.</i> , 2002	Finland	familial and sporadic BC, <i>BRCA1/2</i> negative	case-control study	NA ^b
Thorstenon <i>et al.</i> , 2003	Austria	familial BC	case-control study	NA ^b
Izatt <i>et al.</i> , 1999	UK	early-onset BC (<40y), moderate/absent family history, <i>BRCA1/2</i> negative	case-control study	NA ^b

NA, not applicable (OR not provided because no mutations were found in healthy controls)

^aOR was calculated using the data reported in the paper^bPolymorphisms and VUSs were excluded